Share
Journal Information
Issue
Vol. 27. Issue S2.Oral presentations at the XVI National Congress of the Mexican Association of Hepatology
(January 2022)
Oral Presentations at The XVI National Congress of The Mexican Association of Hepatology
Ann Hepatol. 2022;27 Supl 2:100589
Full text access
VARICEAL VERSUS NON-VARICEAL ETIOLOGY OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH CIRRHOSIS AND RELATED SECONDARY COMPLICATIONS
I.E. Bravo-Espinoza, J.L. Pérez-Hernández, F.A. Lajud-Barquín, R.Y. López-Pérez, M.O. Santana-Montes, P.M. Diego-Salazar, M.F. Higuera de la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.1
Open access
CORRELATION BETWEEN SARCOPENIA AND HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
O. Morales Gutiérrez, A.K. Soto-Martínez, F.Y. Vargas-Durán, P. Alagón-Fernández del Campo, A.D. Santana-Vargas, J.E. Lira-Vera, M.F. Higuera-de la Tijera, J.L. Pérez-Hernández
Ann Hepatol. 2022;27 Supl 2:100589.2
Open access
PREVALENCE AND CHARACTERISTICS OF PORTAL VEIN RECANALIZATION IN CIRRHOTIC PATIENTS ADMITTED WITH PORTAL THROMBOSIS IN A THIRD LEVEL CARE CENTER
C.A. Campoverde-Espinoza, A. Martínez-Tovar, F. Higuera de la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.3
Open access
INITIAL EVALUATION OF KIDNEY FUNCTION IN PATIENTS WITH LIVER CIRRHOSIS OF CEIHET, HIDALGO
R. Contreras-Omaña, M. Baca-García, S. Tellez-Jaen
Ann Hepatol. 2022;27 Supl 2:100589.4
Open access
IMPACT OF REFRACTORY ASCITES ON THE SURVIVAL OF PATIENTS WITH CIRRHOSIS
P.L. Pérez-Santos, M.F. Higuera de la Tijera, D. Santana-Vargas, J.E. Lira-Vera, O. Morales-Gutiérrez, V.M. Mendoza-Martínez, J.L. Pérez-Hernández
Ann Hepatol. 2022;27 Supl 2:100589.5
Open access
EXPERIENCE IN THE USE OF HUMAN ALBUMIN IN COMPLICATIONS OF LIVER CIRRHOSIS AT HOSPITAL JUÁREZ DE MÉXICO
R. Chicas-López, T. Deaquino Reyes, S. Mejía Loza
Ann Hepatol. 2022;27 Supl 2:100589.6
Open access
CHANGES IN CARDIAC FUNCTION IN PATIENTS WITH DECOMPENSATED CHRONIC LIVER FAILURE
M.E. Robles-Villagómez, J.G. Gandara-Calderón, A. Gutiérrez-Atemis, C. Montejo-Velázquez, E. Cerda-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.7
Open access
EFFICACY AND SAFETY OF TERLIPRESSIN INFUSION VS BOLUS TREATMENT IN DIGESTIVE BLEEDING OF VARICEAL ORIGIN AT THE PUEBLA SPECIALTY HOSPITAL, PRELIMINARY RESULTS
N. Moreno-Aguilar, D.E. Meléndez-Mena, M.A. Mendoza-Torres
Ann Hepatol. 2022;27 Supl 2:100589.8
Open access
DIABETES AS A CAUSE OF DECOMPENSATION IN HEPATIC CIRRHOSIS
G. Martínez Ramírez, G. Vargas Ayala
Ann Hepatol. 2022;27 Supl 2:100589.9
Open access
COMPLICATION ASSOCIATED WITH UPPER GASTROINTESTINAL BLEEDING AMONG MEXICAN PATIENTS WITH CIRRHOSIS
F.A. Lajud-Barquin, M.F. Higuera de la Tijera, J.L. Pérez-Hernández, I.E. Bravo-Espinoza, R.Y. López-Pérez, M.O. Santana-Montes, P.M. Diego-Salazar
Ann Hepatol. 2022;27 Supl 2:100589.10
Open access
TRENDS OF CHRONIC LIVER DISEASES IN THE UNIVERSITY HOSPITAL, UANL FOR 25 YEARS. A SINGLE-CENTER EXPERIENCE
L.E. Munoz-Espinosa, C. Trevino-Garcia, I.G. Lopez-Reyna, A. Regalado-Ceballos, P. Cordero-Perez, Y.G. Alonso-Cruz, V.H. Avalos-Gómez, R. Martinez-Macias, ... I.E. Hernandez-Padilla
Ann Hepatol. 2022;27 Supl 2:100589.11
Open access
CAUSES OF DECOMPENSATION IN HOSPITALIZED CIRRHOTIC PATIENTS
A.B. Moreno-Cobos, J.L. Pérez-Hernández, B.A. Enríquez-Constantino, M.Y Carmona-Castillo, E.J. Medina-Ávalos, C.L. Dorantes-Nava, M.F. Higuera-De la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.12
Open access
PREVALENCE AND CLINICAL CHARACTERISTICS OF FATTY HEPATIC DISEASE ASSOCIATED WITH METABOLIC DYSFUNCTION IN A POPULATION WITH NORMAL BODY MASS INDEX. (LEAN MAFLD)
A.L. Ordóñez-Vázquez, D. Pérez, J.P. Soriano, E. Tovar, E. Juárez, M. Uribe, Y.I. López
Ann Hepatol. 2022;27 Supl 2:100589.13
Open access
INCIDENTAL FINDING OF FATTY LIVER IN AUTOPSIES
I.E. Bravo-Espinoza, G. Arist-Urista, M.A. Durán-Padilla, J.L. Pérez-Hernández, R.Y. López-Pérez, P.L. Pérez-Santos, J.L. Montenegro-Tablada, J. Escobedo-Uribe, ... F. Higuera-De la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.14
Open access
FREQUENCY OF RISK FACTORS FOR DEVELOPMENT OF METABOLIC FATTY LIVER DISEASE (MAFLD) IN A CENTER OF CONCENTRATION OF LIVER DISEASES
S. Tellez-Jaen, G. López-Rodríguez, R. Contreras-Omaña, M.A González-Unzaga
Ann Hepatol. 2022;27 Supl 2:100589.15
Open access
PREVALENCE OF COMBINED LIVER DAMAGE IN MEXICAN POPULATION
J.E. Lira-Vera, O. Morales-Gutiérrez, F.Y. Vargas-Durán, P. Alagón-Fernández del Campo, A.K. Soto-Martínez, G. Gutiérrez-Reyes, M. Martínez-Castillo, A.S. Sánchez-Valle, ... J.L. Pérez-Hernández
Ann Hepatol. 2022;27 Supl 2:100589.16
Open access
HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
F- Higuera-de-la-Tijera, N.C. Flores-García, D. Kershenobich, E. Cerda-Reyes, M.S. González-Huezo, J.L. Pérez-Hernández, N. Méndez-Sánchez, O. Morales-Gutiérrez, ... E. Rodríguez-Fuentes
Ann Hepatol. 2022;27 Supl 2:100589.17
Open access
HEPATOCELLULAR CARCINOMA IN VERACRUZ: A SURVEILLANCE COMPARISON BETWEEN TREATMENTS
G.A. Salgado-Álvarez, A.D. Cano-Contreras, G. Martínez-Mier, M.J.J. García-Carvajal, P. Grube-Pagola, I. Morales-García, J.M. Remes-Troche
Ann Hepatol. 2022;27 Supl 2:100589.18
Open access
HEPATOCELLULAR CARCINOMA: CLINICAL AND EPIDEMIOLOGICAL FEATURES IN VERACRUZ
M.J.J. García-Carvajal, A.D. Cano-Contreras, G. Martínez-Mier, G.A. Salgado-Álvarez, I. Morales García, P. Grube-P, J.M. Remes-Troche
Ann Hepatol. 2022;27 Supl 2:100589.19
Open access
A MULTICENTER REAL-WORLD COHORT TO VALIDATE THE EFFICACY AND SAFETY OF DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C, AND RELATED RISK FACTORS FOR NON-SVR IN DECOMPENSATED CIRRHOSIS
F. Higuera-de-la-Tijera, N.C. Flores-García, D. Kershenobich, E. Cerda-Reyes, M.S. González-Huezo, J.L. Pérez-Hernández, N. Méndez-Sánchez, O. Morales-Gutiérrez, ... E. Rodríguez-Fuentes
Ann Hepatol. 2022;27 Supl 2:100589.20
Open access
STUDY OF CONCORDANCE BETWEEN THE DEGREE OF LIVER FIBROSIS ESTIMATED THROUGH APRI AND FIB-4 BIOCHEMICAL SCORES, AND ELASTORESONANCE IN PATIENTS WITH AUTOIMMUNE HEPATITIS
P.D. Flores Rangel, N.A. Bolaños Gómez, L.A. Murrieta González, A.B. Craviotto Rivera, E. Cerda Reyes
Ann Hepatol. 2022;27 Supl 2:100589.21
Open access
GLUCOGENOSIS AS A CAUSE OF INTRAHEPATIC CHOLESTASIS
K.Y. Santoyo López, A Domínguez García
Ann Hepatol. 2022;27 Supl 2:100589.22
Open access
ADDRESSING THE INFILTRATIVE PATTERN: COMPLEX DIAGNOSIS
A.L. Ordóñez-Vázquez, J. Prieto-Nava, F. Ayala-Ochoa, A. Heredia-Jara, L. Montiel-Velázquez, I. López-Méndez
Ann Hepatol. 2022;27 Supl 2:100589.23
Open access
PRIMARY BILIARY CHOLANGITIS COMPLICATED WITH ULCERATIVE COLITIS: A CASE REPORT
J.C. Valles Gonzales, O. García Rodas, N. Pérez y López, C.A. Hernández Cuevas
Ann Hepatol. 2022;27 Supl 2:100589.24
Open access
AUTO IMMUNE HEPATITIS AS A LIVER MANIFESTATION OF COMMON VARIABLE IMMUNODEFICIENCY: A CASE REPORT
O.L. García Rodas, F. Sánchez Salinas, S.M.I. Mejía Loza
Ann Hepatol. 2022;27 Supl 2:100589.25
Open access
PORTA VEIN THROMBOSIS (PVT) IN CIRRHOTIC PATIENTS PRE AND DURING THE PANDEMIC BY SARS-COV2
C.A. Campoverde-Espinoza, A. Martínez-Tovar, M.F. Higuera de la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.26
Open access
HEPATIC FUNCTION ALTERATIONS IN SARS-COV 2 HOSPITALIZED PATIENTS AT HOSPITAL 450, DURANGO
J.S. Jacobo Karam, M.A. Vazquez-Garcia, C.G. Lerma-Burciaga, M.E. Rábago-Sánchez, G. Valencia-Pérez, H.A. Almonte de León, A.G. Calvillo-Carrillo, L.E. Zavala-Fernández, O. López-Gómez
Ann Hepatol. 2022;27 Supl 2:100589.27
Open access
FREQUENCY OF HEPATIC FUNCTION ALTERATION IN MEXICAN PATIENTS WITH COVID-19 AND ITS ASSOCIATION WITH THE SEVERITY OF ACUTE RESPIRATORY DISTRESS SYNDROME: PRELIMINARY RESULTS
A.B. Vera-Heredia, M.I. Mejía-Loza, E.C. Macías-Cortés
Ann Hepatol. 2022;27 Supl 2:100589.28
Open access
RELIABILITY FACTORS FOR THE MEASUREMENT OF HEPATIC STEATOSIS BY MEANS OF A CONTROLLED ATTENUATION PARAMETER BY TRANSIENT ELASTOGRAPHY
M. Figueroa Palafox, E. Juárez-Hernández, Y.I. Lopez-Mendéz
Ann Hepatol. 2022;27 Supl 2:100589.29
Open access
COMPARISON OF SEROLOGICAL MODELS OF LIVER FIBROSIS AGAINST TRANSIENT ELASTOGRAPHY BY FIBROSCAN® IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
J. Aquino-Matus, J. Jiménez-Pavón, M. Uribe, N. Chavez-Tapia
Ann Hepatol. 2022;27 Supl 2:100589.30
Open access
NEOBUXBAMIA TETETZO AS A CAUSE OF DRUG-INDUCED LIVER INJURY
A.C. Chavarín Meza, C. Diéguez-Campa, O. León-Mondragón, L. Juarez-Chavez
Ann Hepatol. 2022;27 Supl 2:100589.31
Open access
HEPATIC MANIFESTATIONS OF INFECTIOUS DISEASES. PRESENTATION OF CLINICAL CASE
S.L. Falcón González, B.M. Morales Matamoros, K.G. Córdova García, F.A. Reynoso Zarzosa
Ann Hepatol. 2022;27 Supl 2:100589.32
Open access
HEPATIC STEATOSIS IN CYSTIC FIBROSIS. APROPOS OF A CASE
S.L. Falcón González, M. Lescas Orozco, Y.S. Sosa Pech, F.A. Reynoso Zarzosa
Ann Hepatol. 2022;27 Supl 2:100589.33
Open access
NEUTROPHILE/LYMPHOCYTE INDEX (IN/L), CREATININE (Cr), AND PROCALCITONIN (PROCAL) AS PREDICTORS OF AMEBIAN LIVER ABSCESS.
C.A. Campoverde-Espinoza, A. Martínez-Tovar, F. Higuera de la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.34
Open access
CLINICAL, BIOCHEMICAL, AND IMAGE CHARACTERISTICS IN PATIENTS WITH A DIAGNOSIS OF AMEBIC AND BACTERIAL LIVER ABSCESS.
C.A. Campoverde-Espinoza, A. Martínez-Tovar, F. Higuera de la Tijera
Ann Hepatol. 2022;27 Supl 2:100589.35
Open access
IMPACT OF RISK FACTORS IN THE SCRUTINY AND DIAGNOSIS OF HEPATITIS C
J. Méndez-Navarro, R.A. Chirino-Sprung, A. Azamar-Alonso, D. Kershenobich
Ann Hepatol. 2022;27 Supl 2:100589.36
Open access
CLEAR CELL HEPATOCELLULAR CARCINOMA, A CASE REPORT
M. Velasco-Gutiérrez, K.M. Ortiz-Aguirre, F.I. Garcia-Juarez, E.M. Zamayoa-Cervantes
Ann Hepatol. 2022;27 Supl 2:100589.37
Open access
FRUCTOSE DIET INDUCES A METABOLIC REPROGRAMMING TO ENHANCE TUMOR AGGRESSIVENESS
L. Chávez-Rodríguez, A. Escobedo-Calvario, A. Simoni-Nieves, L. Bucio, V. Souza, R.U. Miranda Labra, G.C. Enriquez-Cortina, F. Masso, ... L.E. Gómez-Quiroz
Ann Hepatol. 2022;27 Supl 2:100589.38
Open access
ANTIOXIDANT EFFECT OF SPINACH EXTRACT IN LIVER FIBROGENESIS ASSOCIATED TO ACTIVATION OF NRF2/HO-1 IN HYPERGLYCEMIC RATS
J.J. Flores Estrada, A. Cano Martínez, S.M.I. Mejía Loza, A. Vargas González, Z.J. Rodríguez Serrano, R.M. Pérez Gutiérrez, O.L. García Rodas
Ann Hepatol. 2022;27 Supl 2:100589.39
Open access
NAMPT INHIBITION AND INCREASED NAD-BIOAVAILABILITY ATENUATE LIVER DAMAGE IN CCl4-INDUCED MICE CHRONIC LIVER DISEASE
J.A. Gutiérrez buendía, R. Pérez Cabeza de Vaca, G.A. Domínguez Pérez, E. Vera Gomez, A. Hernández Patricio, K. Moreno Vega, M. Salamanca García, J.I. Bustamante Santillan, ... J.A. Suárez Cuenca
Ann Hepatol. 2022;27 Supl 2:100589.40
Open access
“THE EFFECT OF GROWTH DIFFERENTIATION FACTOR 11 (GDF11) ON THE RESPONSE OF TUMOR-ASSOCIATED MACROPHAGES IN HEPATOCELLULAR CARCINOMA DERIVED CELLS”
A. Escobedo-Calvario, L. Chávez-Rodríguez, V. Souza, R.U. Miranda Labra, F. Masso, A. Páez-Arenas, R. Hernández-Pando, L.E. Gómez-Quiroz, María C. Gutiérrez-Ruíz
Ann Hepatol. 2022;27 Supl 2:100589.41
Open access
EFFECT OF SUPPLEMENTATION WITH TYPICAL MEXICAN FOODS (OPTUNA FICUS INDICA, THEOBROMA CACAO AND EDIBLE CRICKETS) IN HIGH-FAT/HIGH-SUGAR DIET-FED MICE
R. Rosas Campos, A. Meza Ríos, S. Rodríguez Sanabria, R. de la Rosa Bibiano, A. Sandoval Rodríguez, J. Armendáriz Borunda
Ann Hepatol. 2022;27 Supl 2:100589.42
Open access
EVALUATION OF THE HEPATOPROTECTOR EFFECT OF A SUPPLEMENT WITH CURCUMA LONGA AGAINST REPERFUSION ISCHEMIA DAMAGE IN AN EXPERIMENTAL MODEL IN WISTAR RATS
P. Cordero- Pérez, AG Flores de Alejandro, L.E. Muñoz-Espinosa, L. Torres-González, D.P. Moreno Peña, D.R. Rodríguez-Rodríguez, E. Pérez-Rodriguez
Ann Hepatol. 2022;27 Supl 2:100589.43
Open access
CHEMOSENSITIZING EFFECTS OF GDF11 IN HUMAN HEPATOCELLULAR CARCINOMA CELLS
N. German-Ramirez, G.I. Domínguez-Gómez, A. Simoni-Nieves, M. Gerardo-Ramírez, L. Bucio-Ortiz, María C. Gutiérrez-Ruiz, Luis E. Gómez-Quiroz
Ann Hepatol. 2022;27 Supl 2:100589.44
Open access
HGF AND PROTECTIVE ROLL IN THE INTESTINAL COLLATERAL DAMAGE BY Α-NAFTILISOTIOCIANATO- INDUCE CHOLESTASIS.
J. Lopez-Ramirez, M. García-Barrera, N. Nuño-Lámbarri, S. Salas-Silva, M.C. Gutiérrez-Ruiz, V. Souza, L.E. Gomez-Quiroz, L. Bucio Ortiz
Ann Hepatol. 2022;27 Supl 2:100589.45
Open access
IGFBP-1 TO 7 AS BIOMARKERS IN STAGES OF LIVER FIBROSIS DURING VIRAL HEPATITIS C
M. Martínez-Castillo, D. Santana-Vargas, J.L. Pérez-Hernández, F. Higuera-De la Tijera, D. Kershenobich, G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.46
Open access
LYMPHOCYTE PROFILE ON PATIENTS WITH CHRONIC AND ACUTE ALCOHOL CONSUMPTION
Z. Medina-Avila, M. Martínez-Castillo, D. Santana-Vargas, Y. Bejar, F. Higuera de la Tijera, J.L. Pérez-Hernández, D. Kershenobich, G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.47
Open access
IL-10 Y TNF-α IN SERUM OF PATIENTS WITH CHRONIC HEPATITIS C AND HEPATIC DAMAGE CHRONIC AND ACUTE FOR ALCOHOL CONSUMPTION
M. Hernandez-Santillan, M. Martínez-Castillo, D. Santana-Vargas, Z. Medina-Avila, A. Hernández-Barragan, J. Limón-Castillo, J.L. Pérez-Hernández, F. Higuera-De la Tijera, ... G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.48
Open access
DETERMINATION OF LEUKOCYTE PROFILE IN CHRONIC ALCOHOL CONSUMPTION
E.A. Alamo-Capula, M. Hernandez Santillan, A. Hernandez-Barragan, S. Sánchez-Valle, I. Altamirano-Mendoza, Z. Medina-Avila, M. Martínez-Castillo, D. Santana-Vargas, ... G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.49
Open access
SERUM DETERMINATION OF MMP-2 AND MMP-9 ACCORDING TO THE PATTERN OF ALCOHOL CONSUMPTION AND IN ALCOHOLIC HEPATIC DISEASE
A. Hernandez-Barragan, M. Martinez-Castillo, J.L. Pérez-Hernández, F. Higuera-De la Tijera, D. Santana-Vargas, D. Kershenobich, G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.50
Open access
COMPARISON OF CXCL-8 and IFN-γ PRODUCTION IN ACUTE AND CHRONIC STAGES OF LIVER DISEASE
I. Altamirano-Mendoza, M. Martínez-Castillo, Z. Medina-Avila, L. García-Islas, J.L. Pérez-Hernández, F. Higuera-De la Tijera, D. Santana-Vargas, J. Cordova-Gallardo, ... G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.51
Open access
OXIDATIVE DAMAGE MARKERS IN ALCOHOLIC HEPATITIS
S. Sánchez-Valle, M. Martínez-Castillo, Z. Medina-Avila, J. Castillo-Limón, L. García-Islas, M. Hernández-Santillan, A. Hernández-Barragán, D. Santana-Vargas, ... G. Gutiérrez-Reyes
Ann Hepatol. 2022;27 Supl 2:100589.52
Open access
TOTAL CHOLESTEROL / HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO, TRIGLYCERIDES / HIGH DENSITY LIPOPROTEIN CHOLESTEROL WITH THE CONTROLLED ATTENUATION PARAMETER (CAP) IN NON-ALCOHOLIC FATTY LIVER
C.N. Ascencio Barrientos, L.C. Barrios Lupitou, R.M. Rivera Orellana, A.G. Rivera Flores, M.I.S. Mejía Loza
Ann Hepatol. 2022;27 Supl 2:100589.53
Open access
DIFFERENTIAL PROFILE OF PRO-INFLAMMATSORY / ANTI-INFLAMMATORY CYTOKINES AND MALONDIALDEHYDE IN PATIENTS WITH ALCOtHOL-INDUCED OR OBESITY OR MIXED INJURY
L. Torres-González, L.R. Aguilar Rivera, D.P. Moreno-Peña, O.H. Mendoza Hernández, A.A. Lugo Rodriguez, M.E. Posada Lerma, L.E. Muñoz Espinosa, H. Nañez Terreros, P. Cordero-Pérez
Ann Hepatol. 2022;27 Supl 2:100589.54
Open access
PROFILE OF PRO AND ANTI-INFLAMMATORY CYTOKINES IN PATIENTS WITH CHRONIC LIVER DISEASE IN THE COMPENSATION, INFLAMMATION AND IMMUNOSUPPRESSION PHASES
B. Tijerina-Soto, P. Cordero-Pérez, D.P. Moreno-Peña, C. Treviño-García, L.E. Muñoz-Espinosa
Ann Hepatol. 2022;27 Supl 2:100589.55
Open access
CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A PROMOTER IN THE DEVELOPMENT OF FIBROSIS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
E. Morales, C. Guzmán-Arriaga, M.A. Díaz-Castro, F. Higuera-de-la-Tijera, D. Santana-Vargas, E. Bautista Ubaldo, J.E. Lira-Vera, O. Morales-Gutiérrez, J.L. Pérez-Hernández
Ann Hepatol. 2022;27 Supl 2:100589.56
Open access
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness
L. Barrett, S. Rosati, M. Garcia-Retortillo, H. Wedemeyer, E. Teti, FA Pérez Hernández, M. Selfridge, A. Wong, ... V. Calvaruso
Ann Hepatol. 2022;27 Supl 2:100589.57
Open access
Publish in
Annals of Hepatology
Special content about COVID-19
- Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study
- Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells
- P-2 NASH IS IMPROVED THROUGH MODIFICATIONS IN H3K9 METHYLATION BY PIRFENIDONE ACTING AS JMJD2B DEMETHYLASE ANTAGONIST.
- O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
Affiliated societies
